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Introduction: Met activation by gene amplification and its ligand, 
hepatocyte growth factor (HGF), imparts resistance to epidermal 
growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in 
 EGFR-mutant lung cancer. We recently reported that Met activation by 
HGF stimulates the production of vascular endothelial growth factor 
(VEGF) and facilitates angiogenesis, which indicates that HGF induces 
EGFR-TKI resistance and angiogenesis. This study aimed to determine 
the effect of triple inhibition of EGFR, Met, and angiogenesis on HGF-
triggered EGFR-TKI resistance in EGFR-mutant lung cancer.
Methods: Three clinically approved drugs, erlotinib (an EGFR 
inhibitor), crizotinib (an inhibitor of anaplastic lymphoma kinase 
and Met), and bevacizumab (anti-VEGF antibody), and  TAS-115, a 
novel dual TKI for Met and VEGF receptor 2, were used in this study. 
EGFR-mutant lung cancer cell lines PC-9, HCC827, and HGF-gene–
transfected PC-9 (PC-9/HGF) cells were examined.
Results: Crizotinib and TAS-115 inhibited Met phosphorylation 
and reversed erlotinib resistance and VEGF production triggered by 
HGF in PC-9 and HCC827 cells in vitro. Bevacizumab and TAS-115 
inhibited angiogenesis in PC-9/HGF tumors in vivo. Moreover, the 
triplet erlotinib, crizotinib, and bevacizumab, or the doublet erlotinib 
and TAS-115 successfully inhibited PC-9/HGF tumor growth and 
delayed tumor regrowth associated with sustained tumor vasculature 
inhibition even after cessation of the treatment.
Conclusion: These results suggest that triple inhibition of EGFR, 
HGF/Met, and VEGF/VEGF receptor 2, by either a triplet of clini-
cal drugs or TAS-115 combined with erlotinib, may be useful for 
controlling progression of EGFR-mutant lung cancer by reversing 
EGFR-TKI resistance and for inhibiting angiogenesis.
Key Words: Hepatocyte growth factor, Vascular endothelial growth 
factor, Epidermal growth factor receptor-tyrosine kinase inhibitor 
resistance, Lung cancer, Epidermal growth factor receptor mutation.
(J Thorac Oncol. 2014;9: 775–783)
Lung cancer is the leading cause of cancer-related deaths worldwide. Recent advances in molecular biology have 
identified driver oncogenes such as epidermal growth factor 
receptor (EGFR) mutations or the echinoderm microtubule–
associated protein-like 4/anaplastic lymphoma kinase (ALK) 
fusion gene in non–small-cell lung cancer (NSCLC). In the 
treatment of NSCLCs harboring these driver oncogenes, the 
use of EGFR tyrosine kinase inhibitors (TKIs; such as gefi-
tinib and erlotinib) and an ALK inhibitor (such as crizotinib) 
to block driver oncogene survival signals resulted in marked 
tumor regression.1–4 Despite these clinical successes, tumors 
acquire resistance to those agents in almost all cases during 
the course of therapy.5
Recently, several mechanisms of EGFR-TKI resistance 
have been identified and classified as follows: (1) alteration of 
the target EGFR gene (e.g., T790M gatekeeper mutation)6,7; 
(2) activation of bypass resistance signals (e.g., Met gene 
amplification,8 hepatocyte growth factor [HGF] overexpres-
sion,9 and activation of the nuclear factor-kappa B (NFkB)
pathway10 and Gas6-AXL axis)11; and (3) other mechanisms 
such as transformation to small-cell lung cancer,12–14 epithelial-
to-mesenchymal transition,15–17 alteration of microRNA,18 and 
down-regulation of MED12.19 Previously, we demonstrated 
that HGF activates, through the Met/PI3K/Akt pathway, 
bypass signals that trigger resistance; overexpression of HGF 
was observed more frequently than T790M and Met ampli-
fication in tumors from patients with NSCLC who acquired 
EGFR-TKI resistance in a Japanese cohort.20 These findings 
indicate that HGF is a clinically relevant target for overcoming 
EGFR-TKI resistance in EGFR-mutant lung cancer.
Angiogenesis is essential for the progression of various 
types of solid tumors, including NSCLC. Vascular endothe-
lial growth factor (VEGF) is the most prominent proangio-
genic molecule and is considered to be a therapeutic target 
in NSCLC. We previously reported that overexpressed HGF 
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stimulates VEGF production by means of phosphorylation 
of Met/Gab1 and promotes tumor growth by stimulating 
angiogenesis in EGFR-mutant lung cancer models,21 which 
indicates that HGF is a critical inducer of not only EGFR-
TKI resistance but also angiogenesis in EGFR-mutant lung 
cancer. Therefore, we hypothesized that triple inhibition of 
the driver signal (EGFR), bypass resistance signal (Met), 
and angiogenesis (VEGF) may be beneficial for controlling 
the progression of EGFR-mutant lung cancer with HGF-
triggered EGFR-TKI resistance.
EGFR-TKIs, erlotinib, gefitinib, ALK-TKI, crizotinib, 
and the anti-VEGF antibody bevacizumab have been clinically 
approved as molecularly targeted drugs in many countries. 
Crizotinib is known to have activity against Met in addi-
tion to ALK and c-ros oncogene 1, receptor tyrosine kinase 
(ROS1).22,23 In the present study, we investigated the therapeu-
tic effect of triple inhibition against HGF-triggered, EGFR-
TKI–resistant lung cancer harboring an EGFR mutation by 
using clinically available targeted drugs, namely, erlotinib, 
crizotinib, and bevacizumab. We further assessed the thera-
peutic potential of erlotinib and TAS-115 (Supplementary 
Figure 1, Supplementary Digital Content 1, http://links.lww.
com/JTO/A570), a novel VEGF receptor 2 (VEGFR-2) inhibi-
tor, which can be orally administered and has Met inhibitory 
activity, and we compared this doublet treatment with the 
clinically available triplet. In this study, we demonstrate that 
the doublet inhibited the progression of HGF-overexpressing 
EGFR-mutant lung cancer more efficiently than the clinically 
available triplet treatment. Moreover, TAS-115 combined with 
erlotinib also controlled tumor growth well and, remarkably, 
delayed regrowth even after cessation of the treatment.
MATERIALS AND METHODS
Cell Cultures and Reagents
The EGFR-mutant human lung adenocarcinoma cell 
lines PC-9 (del E746_A750) and HCC827, with deletions 
in EGFR exon 19, were purchased from Immuno-Biological 
Laboratories Co. (Gunma, Japan) and from American Type 
Culture Collection (Manassas, VA) respectively.21 Human 
HGF-gene transfectant (PC-9/HGF) and vector control (PC-9/
Vec) cells were established as previously described.24 These 
cell lines were maintained in  RPMI-1640 medium supple-
mented with 10% fetal bovine serum (FBS) and antibiotics. 
All cells were passaged for less than 3 months before renewal 
from frozen, early-passage stocks. The human embryonic 
lung fibroblast cell line MRC-5 was purchased from the 
Health Science Research Resources Bank (Osaka, Japan). 
MRC-5 (P30–35) cells were maintained in Dulbecco’s modi-
fied Eagle’s medium with 10% FBS, 100 units/ml penicillin, 
and 100 μg/ml streptomycin. Human dermal microvascular 
endothelial cells (HMVECs) were incubated in RPMI-1640 
medium with 10% FBS (control), RPMI-1640 medium with 
10% FBS plus VEGF, or  HuMedia-MvG with different con-
centrations of TAS-115 for 72 hours. Thereafter, cell viability 
was determined by thiazolyl blue tetrazolium bromide (MTT) 
assay. Cells were regularly screened for mycoplasma by using 
MycoAlert Mycoplasma Detection Kits (Lonza, Rockland, 
ME). The cell lines were authenticated at the laboratory of 
the National Institute of Biomedical Innovation (Osaka, 
Japan) by short tandem repeat analysis. TAS-115 was synthe-
sized by Taiho Co., Ltd (Tokyo, Japan). Erlotinib and crizo-
tinib were obtained from Selleck Chemicals (Houston, TX). 
Bevacizumab was obtained from Chugai Pharma (Tokyo, 
Japan). Human recombinant HGF was prepared as previously 
described.24
Production of HGF and VEGF in 
Cell Culture Supernatants
Cells (2 × 105) were cultured in a 2 ml of culture medium 
with 10% FBS for 24 hours, washed with phosphate-buffered 
saline (PBS), and incubated for 48 hours in the medium sup-
plemented with 10% FBS. In some experiments, HGF was 
added to the medium. The culture media was harvested and 
centrifuged, and the supernatants were stored at −80°C until 
analysis. The concentrations of HGF and VEGF were deter-
mined by IMMUNIS HGF EIA (Institute of Immunology, 
Tokyo, Japan) or Quantikine VEGF enzyme-linked immu-
nosorbent assay (R&D Systems, Minneapolis, MN), respec-
tively, according to the respective manufacturer’s protocol. All 
samples were run in duplicate. Color intensity was measured 
at 450 nm by using a spectrophotometric plate reader. Growth 
factor concentrations were determined by comparison with 
standard curves. The detection limits for HGF and VEGF 
were 100 and 31 pg/ml, respectively.
Cell Viability Assay
Cell growth was measured using the MTT dye reduc-
tion method.24 Tumor cells were plated into 96-well plates at 
a density of 2 × 103 cells/100 ml RPMI-1640 medium with 
10% FBS per well. After 24-hour incubation, various reagents 
were added to each well, and the cells incubated for a further 
72 hours, followed by the addition of 50 μl of MTT solution 
(2 mg/ml; Sigma, St. Louis, MO) to each well and incuba-
tion for 2 hours. The media containing MTT solution was 
removed, and the dark blue crystals were dissolved by add-
ing 100 ml of dimethyl sulfoxide. The absorbance of each well 
was measured with a microplate reader at test and reference 
wavelengths of 550 and 630 nm, respectively. The percent-
age of growth is shown relative to untreated controls. Each 
reagent concentration was tested at least in triplicate during 
each experiment, and each experiment was conducted at least 
three times.
Antibodies and Western Blotting
Protein aliquots of 25 μg each were resolved by sodium 
dodecyl sulfate-polyacrylamide gel (Bio-Rad, Hercules, CA) 
electrophoresis and transferred to polyvinylidene difluoride 
membranes (Bio-Rad). After washing four times, the mem-
branes were incubated with Blocking One (Nacalai Tesque, 
Kyoto, Japan) for 1 hour at room temperature and overnight at 
4°C with primary antibodies to β-actin (13E5), Met (25H2), 
phospho-Met (Y1234/Y1235;3D7), phospho-EGFR (Y1068), 
Akt, phospho-Akt (Ser473; 736E11), VEGFR-2 (55B11), 
phospho-VEGFR-2 (Tyr951;15D2), human EGFR (1 μg/ml), 
human/mouse/rat Erk1/Erk2 (0.2 μg/ml), and p-Erk1/Erk2 
(T202/Y204; 0.1 μg/ml; R&D Systems). After three washes, 
777Copyright © 2014 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 6, June 2014 Inhibition of EGFR/Met/VEGFR-2 Against EGFR-TKI-Resistance
the membranes were incubated for 1 hour at room tempera-
ture with species-specific, horseradish peroxidase–conjugated 
secondary antibodies. Immunoreactive bands were visualized 
with Super Signal West Dura Extended Duration Substrate 
(Thermo Fisher Scientific, Waltham, MA) and an enhanced 
chemiluminescence substrate (Pierce Biotechnology, 
Rockford, IL). Each experiment was conducted at least three 
times independently.
Coculture of Lung Cancer Cells with 
Fibroblasts or Endothelial Cells
Cells were cocultured in Transwell collagen–coated 
chambers separated by an 8-mm (BD Biosciences, San Jose, 
CA) or 3-mm (Corning, Tewksbury, MA) pore size filter. Tumor 
cells (8 × 103 cells/800 ml) with or without TAS-115 (1.0 μmol/
liter) or erlotinib (0.3 μmol/liter) in the lower chamber were 
cocultured with MRC-5 (1 × 104 cells/300 μl) cells in the upper 
chamber for 72 hours. The upper chamber was then removed, 
200 μl of MTT solution was added to each well, and the cells 
were incubated for 2 hours at 37°C. The media was removed, 
and the dark blue crystals in each well were dissolved in 400 μl 
of dimethyl sulfoxide. Absorbance was measured with an MTP-
120 Microplate reader (Corona Electric, Ibaraki, Japan) at test 
and reference wavelengths of 550 and 630 nm, respectively. The 
percentage of growth was measured relative to untreated con-
trols. All samples were assayed at least in triplicate, with each 
experiment conducted three times independently.
Subcutaneous Xenograft Models
Nude mice (male, 5–6 weeks old) were obtained from 
Clea (Tokyo, Japan). Cultured tumor cells (PC-9/Vec or  PC-9/
HGF) were implanted subcutaneously into the flanks of each 
mouse at 3 × 106 cells/0.1 ml. When tumor volumes reached 
100 to 200 mm3, the mice (n = 5 per group) were randomized 
to the following groups: (1) no treatment (control group), (2) 
only 50 mg/kg of erlotinib orally, (3) only 25 mg/kg of crizotinib 
orally, (4) only 100 μg/mouse of bevacizumab intraperitoneally, 
(5) only 75 mg/kg of TAS-115 orally, (6) erlotinib and crizotinib, 
(7) crizotinib and bevacizumab, (8) erlotinib and bevacizumab, 
(9) erlotinib, crizotinib, and bevacizumab, and (10) erlotinib and 
TAS-115. Each tumor was measured in two dimensions three 
times a week, and the volume was calculated using the follow-
ing formula: tumor volume (mm3) = 1/2 (length (mm) × (width 
(mm))2). All animal experiments complied with the Guidelines 
for the Institute for Experimental Animals, Kanazawa University 
Advanced Science Research Center (Approval No. AP-122505).
Histological Analyses
For detection of endothelial cells (CD31), 5-μm-
thick frozen sections of xenograft tumors were fixed with 
cold acetone and washed with PBS. Then, endogenous per-
oxidase activity was blocked by incubation in 3% aque-
ous H
2
O
2
 for 10 minutes. After treatment with 5% normal 
horse serum, the sections were incubated with primary 
antibodies to mouse CD31 (MEC13.3; BD Biosciences). 
After probing with  species-specific, biotinylated second-
ary antibodies, the sections were incubated for 30 minutes 
with avidin–biotinylated peroxidase complex by using a 
Vectastain ABC kit (Vector Laboratories, Burlingame, CA). 
The  3,3′-diaminobenzidine tetrahydrochloride Liquid System 
(DAKO, Glostrup, Denmark) was used to detect immunos-
taining. Omission of the primary antibody served as a nega-
tive control. Terminal deoxynucleotidyl transferase–mediated 
deoxyuridine  triphosphate-biotin nick end-labeling stain-
ing was performed using the Apoptosis Detection System 
(Promega Corporation, Madison, WI). In brief, 5-μm-thick 
frozen sections of xenograft tumors were fixed with PBS con-
taining 4% formalin. The slides were washed with PBS and 
permeabilized with 0.2% Triton X-100. The samples were 
then equilibrated, and DNA strand breaks were labeled with 
 fluorescein-12-2-deoxy-uridine-5-triphosphate (fluorescein-
12-dUTP) by adding the nucleotide mixture and the termi-
nal deoxynucleotidyl transferase enzyme. The reaction was 
stopped with saline sodium citrate, and the localized green 
fluorescence of apoptotic cells was detected by fluorescence 
microscopy (×200). The five areas containing the highest 
numbers of stained cells within a section were selected for 
histologic quantitation by light or fluorescent microscopy at a 
×400 magnification. All results were independently evaluated 
by three investigators (JN, TN, and ST).
Statistical Analysis
Differences were analyzed by one-way analysis of vari-
ance. All statistical analyses were carried out using GraphPad 
Prism Ver. 4.01 (GraphPad Software, Inc., La Jolla, CA). A p 
value of less than 0.01 was considered statistically significant.
RESULTS
Effect of Crizotinib and TAS-115 on Bypass  
Resistance Signals Triggered by Exogenous  
HGF In Vitro
In the first set of experiments, we examined the effect 
of crizotinib and TAS-115 on exogenously added HGF-
triggered EGFR-TKI resistance in vitro. PC-9 and HCC827 
cells are highly sensitive to erlotinib, whereas exogenously 
added HGF induces resistance to erlotinib in both cell lines. 
Crizotinib on its own discernibly inhibits the growth of 
PC-9 cell at high concentrations, consistent with its mul-
tikinase activities, and it remarkably sensitizes the cell to 
erlotinib even in the presence of HGF. TAS-115 does not 
affect the growth of PC-9 or HCC827 cells at concentrations 
less than 10 μmol/liter; however, the combined use of TAS-
115 with erlotinib reverses HGF-induced resistance in the 
cell lines in a  concentration-dependent manner (Figs. 1A, 
B and 2A, B, and Supplementary Figure 2, Supplementary 
Digital Content 2, http://links.lww.com/JTO/A571). We 
previously reported that stromal fibroblasts are a source 
of exogenous HGF for  EGFR-TKI–naive NSCLC and that 
fibroblast-derived HGF induces resistance to gefitinib and 
erlotinib in PC-9 and HCC827 cells.25 Crizotinib and TAS-
115 reverse the erlotinib resistance of PC-9 cells induced by 
coculturing with MRC-5 cells (Supplementary Figure 3A, 
B, Supplementary Digital Content 3, http://links.lww.com/
JTO/A572). These results indicate that both crizotinib and 
TAS-115 can reverse the EGFR-TKI resistance induced by 
exogenous HGF in vitro.
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Effect of Crizotinib and  TAS-115 on Bypass  
Resistance Signals Triggered by Endogenous HGF
Previously, we showed that HGF is predominantly pres-
ent in tumor cells of patients with NSCLC with acquired 
resistance to EGFR-TKIs and that transient HGF-gene trans-
fection into PC-9 cells results in resistance to EGFR-TKIs.20 
We, therefore, generated a stable HGF-gene transfectant in 
PC-9 cells (PC-9/HGF) and assessed the effects against con-
tinuously produced endogenous HGF. PC-9/HGF cells secrete 
high levels of HGF and become resistant to erlotinib, whereas 
PC-9 or the vector control PC-9/Vec cells do not. Although 
TAS-115 does not affect the growth of PC-9/HGF cells, 
crizotinib discernibly inhibits it at high concentrations. The 
combination of crizotinib or TAS-115 with erlotinib success-
fully reverses the resistance of PC-9/HGF cells (Fig. 2A–G). 
Using Western blotting, we examined the effects of crizotinib 
and TAS-115 on signal transduction in PC-9/Vec and PC-9/
HGF cells (Fig. 2H–I). We found that erlotinib inhibits the 
phosphorylation of EGFR and ErbB3 in PC-9/Vec cells, 
thereby inhibiting the phosphorylation of Akt and extracel-
lular signal-regulated kinase 1/2 (ERK1/2). Met phosphory-
lation is observed in PC-9/HGF cells but not in  PC-9/Vec 
cells. However, erlotinib fails to inhibit phosphorylation of 
Akt or Erk1/2 in the presence of HGF. Both crizotinib and 
TAS-115 suppress the constitutive phosphorylation of Met 
but not EGFR, ErbB3, or downstream Akt and ERK1/2. HGF 
stimulates the phosphorylation of Met, but the combined use 
of crizotinib or TAS-115 with erlotinib inhibits the phos-
phorylation of Met, Akt, and Erk1/2. These results suggest 
that crizotinib and TAS-115, when combined with erlotinib, 
reverse HGF-triggered erlotinib resistance by inhibiting the 
Met/Gab1/PI3K/Akt pathway.
Effect of Crizotinib and TAS-115 on 
Angiogenesis In Vitro and In Vivo
As we reported previously,21 exogenous and endogenous 
HGF stimulated VEGF production in the PC-9 cancer cell line. 
Both crizotinib and TAS-115 inhibit VEGF production, pre-
sumably because of inhibiting Met activation by HGF (Fig. 3A, 
B). We also assessed the effect of crizotinib, TAS-115, and 
bevacizumab on the growth of HMVECs. VEGF promoted 
HMVEC viability, whereas TAS-115 and bevacizumab, but 
not crizotinib, inhibit VEGF-stimulated viability of HMVECs 
in a dose-dependent manner (Fig. 3C, D). We also explored the 
potential of TAS-115 against VEGFR-2. Western blot analysis 
indicated that VEGFR-2 is phosphorylated by VEGF stimu-
lation in HMVECs, and TAS-115 and bevacizumab show an 
inhibitory effect (Supplementary Figure 4, Supplementary 
Digital Content 4, http://links.lww.com/JTO/A573). We next 
examined the effect on in vivo angiogenesis by using  short-term 
treatment models. Nude mice with established subcutaneous 
tumors (tumor volume approximately 100 mm3) were treated 
with erlotinib with or without crizotinib, bevacizumab, and/or 
TAS-115, and tumor vascularization was determined on day 4 
(Fig. 4A, B). In PC-9/Vec tumors, treatment with erlotinib 
alone, TAS-115 alone, or erlotinib with TAS-115 inhibited 
vascularization. PC-9/HGF tumors have more vascularization 
than PC-9/Vec tumors. In PC-9/HGF tumors, treatment with 
bevacizumab, but not erlotinib or crizotinib, inhibited vascular-
ization. We found that TAS-115 inhibited vascularization more 
potently than bevacizumab. Under these experimental condi-
tions, treatment with erlotinib plus crizotinib inhibited vascu-
larization. Importantly, erlotinib plus TAS-115 more potently 
inhibited vascularization, compared with erlotinib plus crizo-
tinib, with or without bevacizumab. These results indicate that 
TAS-115 has a high potential to inhibit angiogenesis in vivo in 
EGFR-mutant tumors that produce high levels of HGF. We also 
confirmed that treatment with crizotinib or TAS-115 inhibits 
the phosphorylation of EGFR and Met in vivo (Supplementary 
Figure 5, Supplementary Digital Content 5, http://links.lww.
com/JTO/A574).
Effect of Combined Treatment on Growth 
of HGF-Overexpressing Tumors In Vivo
Nude mice bearing established subcutaneous tumors 
(tumor volume approximately 100 mm3) were treated with 
erlotinib with or without crizotinib, bevacizumab, and/or 
 TAS-115 for 39 days. The treatment was feasible, and no 
FIGURE 1.  Combined use of crizotinib or TAS-115 with erlotinib reverses resistance to EGFR-TKI induced by exogenous HGF.  
A and B, PC-9 cells were incubated with or without erlotinib or crizotinib and TAS-115 in the presence or absence of HGF (20 
ng/ml) for 72 hours. Cell viability was determined by MTT assay. Bars show SD. The data shown are representative of five 
independent experiments with similar results. EGFR, epidermal growth factor receptor; EGFR-TKI, EGFR-tyrosine kinase inhibitor; 
HGF, hepatocyte growth factor; MTT, Thiazolyl Blue Tetrazolium Bromide.
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adverse events, including loss of weight, were observed. 
Tumor volumes on day 39 are shown in Figure 5A and B (tumor 
growth curves over time are shown in Supplementary Figure 6, 
Supplementary Digital Content 6, http://links.lww.com/JTO/
A575). Erlotinib markedly inhibited the growth of  PC-9/Vec 
tumors, but TAS-115 inhibited it only modestly (81.7% and 
40%, respectively). In PC-9/HGF tumors, erlotinib alone and 
crizotinib alone inhibited tumor growth only slightly (30% 
and 31.9%, respectively). Moreover, bevacizumab alone and 
TAS-115 alone inhibited tumor growth modestly (67% and 
76.6%, respectively). Erlotinib plus crizotinib, with or without 
bevacizumab, inhibited tumor growth markedly (87.1% and 
88.3%, respectively). Importantly, erlotinib plus TAS-115 fur-
ther inhibited tumor growth significantly (93.7%).
Effect of Combined Treatment on 
Regrowth of HGF-Overexpressing Tumors 
after Cessation of the Treatment
We further evaluated the effect on regrowth of  PC-9/
HGF tumors after cessation of drug treatment. After 10 days 
of cessation, tumors treated with erlotinib plus crizotinib with 
or without bevacizumab regrew to 4.5 and 3.3 times their ini-
tial size at the start of cessation, respectively. Tumors treated 
with erlotinib plus TAS-115 regrew to only 1.7 times their 
initial size (Fig. 6A). To explore the mechanism of this phe-
nomenon, we again evaluated tumor vascularization on day 
49 (10 days after the start of cessation). Consistent with an 
inhibitory effect against tumor regrowth, vessel density was 
high (104.6 ± 7.3) and modest (68.6 ± 8.0) in tumors treated 
with erlotinib plus crizotinib without and with bevacizumab, 
respectively, whereas vessel density in the tumors treated with 
erlotinib plus TAS-115 was very low (37.8 ± 3.5; Fig. 6B). 
However, the number of apoptotic cells was low (1.5 ± 0.6), 
modest (7.3 ± 5.7), and high (22.7 ± 6.4) in the tumors treated 
with erlotinib plus crizotinib, crizotinib and bevacizumab, 
and TAS-115, respectively. These results suggest that erlotinib 
plus TAS-115 prevents tumor regrowth, even after cessation, 
by means of sustained inhibition of angiogenesis.
DISCUSSION
In the present study, we demonstrated that combined 
use of erlotinib and TAS-115, a novel angiogenesis inhibi-
tor with Met inhibitory activity, and the use of a triplet of 
clinically available drugs (such as erlotinib, crizotinib, and 
bevacizumab) could inhibit the growth of HGF-triggered 
EGFR-TKI–resistant tumors containing EGFR mutations. 
FIGURE 2.  Combined use of crizotinib or TAS-115 with erlotinib reverses resistance to EGFR-TKI induced by endogenous HGF. 
A, PC-9/Vec and PC-9/HGF cells were incubated with or without erlotinib for 72 hours. Cell viability was determined by MTT 
assay. Bars show SD. B and D, PC-9/Vec and PC-9/HGF cells were treated with crizotinib or TAS-115 for 72 hours. C–G, PC-9/Vec 
and PC-9/HGF cells were incubated with or without erlotinib (0.3 μmol/liter) with or without crizotinib (0.3 μmol/liter) and TAS-
115 (1.0 μmol/liter) for 72 hours. The data shown are from three independent experiments with similar results. H and I, PC-9/
HGF cells were incubated with TAS-115 (1.0 μmol/liter) or crizotinib (0.3 μmol/liter) and/or erlotinib (0.3 μmol/liter) for 1 hour. 
Thereafter, cell lysates were harvested, and phosphorylation of the indicated proteins was determined by Western blot analysis. 
EGFR, epidermal growth factor receptor; EGFR-TKI, EGFR-tyrosine kinase inhibitor; HGF, hepatocyte growth factor; MTT, thiazolyl 
blue tetrazolium bromide.
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Moreover,  TAS-115 combined with erlotinib remarkably 
delayed the regrowth of the HGF-triggered EGFR-TKI–
resistant tumors.
Because we reported that HGF is a resistance factor to 
EGFR-TKI in EGFR-mutant lung cancer,9 HGF has been shown 
to induce resistance to various molecularly targeted drugs in 
different types of cancers with driver oncogenes. HGF causes 
resistance to a selective ALK inhibitor26 and a BRAF inhibi-
tor27 in lung cancer with ALK rearrangement and melanoma 
with BRAF mutation, respectively, by inducing bypass signals 
that trigger resistance. Moreover, HGF restores angiogenesis 
associated with Met expression in tumor vascular endothelial 
cells and thus induces resistance to sunitinib in various types of 
cancer.28 These observations indicate that HGF induces resis-
tance to molecularly targeted drugs by multiple mechanisms; 
therefore, it is an important therapeutic target for circumvent-
ing resistance to various molecularly targeted drugs.
HGF and its receptor Met have a close relation with VEGF. 
Anti-VEGF treatment resulted in a remarkable  up-regulation of 
Met expression in tumors.29  Hypoxia-stimulated expression of 
VEGF,30 Met,29 and Neuropilin1 (NRP1), a receptor of VEGF, 
promotes tumor progression.29,31 Furthermore, it was reported 
that serum levels of HGF and VEGF were inversely correlated 
with the clinical response to EGFR-TKIs in lung cancer.32–34 
In addition, a dual inhibitor of VEGFR-2 and Met (XL-184) 
was shown to have completely suppressed the invasion and 
metastasis in a pancreatic cancer model in vivo.29 These studies 
indicate the rationale for simultaneous inhibition of the HGF-
Met and VEGF/VEGFR-2 axes for cancer therapy.
In line with our previous results, we observed that inhi-
bition of both the driver signal (EGFR) and the resistance sig-
nal (Met) remarkably suppressed the growth of HGF-triggered 
EGFR-TKI–resistant tumors in vivo. However, the tumors 
regrew immediately after the cessation of the dual inhibition, 
which indicated the presence of cancer cells with proliferating 
potential that persisted continuously throughout the dual inhi-
bition. Mechanisms of the resistance to dual inhibition should 
be clarified in the near future.
Additional inhibition of angiogenesis by VEGF neu-
tralization or VEGFR inhibition in addition to dual inhibition 
(EGFR and Met) could further inhibit growth of HGF-triggered 
EGFR-TKI–resistant tumor and delay regrowth of the tumors 
after cessation of the treatment. Bevacizumab in combina-
tion with cytotoxic chemotherapy has been shown to prolong 
progression-free survival in various solid tumors. Our results 
suggest that the angiogenesis inhibitor in combination with 
molecularly targeted drugs such as EGFR-TKI and  Met-TKI, 
which directly act on cancer cells, may also delay tumor 
progression.
It is still controversial whether tumor blood vessels 
rapidly regrow after cessation of VEGF inhibition. Mancuso 
et al.35 reported that tumor vasculature regrew within 7 days of 
FIGURE 3.  Crizotinib and TAS-115 
inhibits VEGF production by cancer 
cells and endothelial proliferation. A 
and B, Tumor cells were incubated 
with or without HGF (50 ng/ml) in 
the presence of different concentra-
tions of crizotinib or TAS-115 for 48 
hours. Thereafter, supernatants were 
harvested, and the number of tumor 
cells was counted. VEGF concentration 
in the supernatants was determined 
by ELISA. VEGF levels corrected by the 
tumor cell number are shown. C and 
D, HMVECs were incubated in RPMI-
1640 medium with 10% FBS (control) 
or RPMI-1640 medium with 10% FBS 
in the presence or absence of VEGF (50 
ng/ml) with different concentrations 
of TAS-115, crizotinib, or bevacizumab 
for 72 hours. Thereafter, cell viability 
was determined by MTT assay. Bars 
show SD. The data shown are from 
three independent experiments with 
similar results. VEGF, vascular endo-
thelial growth factor; HGF, hepatocyte 
growth factor; ELISA, enzyme-linked 
immunosorbent assay; HMVECs, 
human dermal microvascular endothe-
lial cells; FBS, fetal bovine serum; MTT, 
thiazolyl blue tetrazolium bromide.
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cessation of VEGFR inhibitors (given for 7 days) in the RIP-
Tag2 pancreatic cancer model and the Lewis lung carcinoma-
xenograft model. Bagri et al.36 showed that  long-term (7 weeks) 
treatment with an anti-VEGF antibody prevented the regrowth 
of tumors compared with control or short-term (2 weeks) treat-
ment, but the effect of the  long-term treatment on vasculature 
regrowth after cessation was not well elucidated. In the present 
study, we demonstrated that regrowth of tumor vasculature was 
inhibited even after cessation for 10 days of treatment when, 
before that, continuous treatment (for 39 days) consisted of 
bevacizumab plus erlotinib and crizotinib or TAS-115 plus erlo-
tinib; and this inhibition was associated with a high number of 
apoptotic cells in the tumors and delayed tumor regrowth. These 
effects were more remarkable with TAS-115 plus erlotinib than 
with the triplet treatment in our experimental conditions. It is 
unclear why continuous triple inhibition, especially by TAS-
115 plus erlotinib, delayed the recovery of tumor angiogenesis. 
One possible explanation is that continuous treatment with 
FIGURE 4.  Treatment with erlotinib 
plus TAS-115 inhibits angiogenesis in 
PC-9/HGF tumors in vivo. Nude mice 
bearing PC-9/Vec or PC-9/HGF tumors 
(approximately 100 mm3 in size) 
were administered erlotinib and/or 
crizotinib and/or TAS-115 orally, once 
daily for 4 days, and/or bevacizumab 
intraperitoneally only once. A, The 
mice were killed on day 4, and the 
tumors were harvested. B, Numbers of 
tumor vessels (mean ± SE) determined 
by CD31 immunohistochemical stain-
ing are shown for groups contain-
ing five mice each. Representative 
graphs are shown. The data shown 
are representative of two independent 
experiments with similar results. HGF, 
hepatocyte growth factor.
FIGURE 5.  Treatment with erlotinib 
plus TAS-115 inhibits the growth of 
PC-9/HGF tumors in vivo. A and B, 
Nude mice bearing PC-9/Vec or PC-9/
HGF tumors (approximately 100 mm3 
in size) were administered erlotinib 
and/or crizotinib and/or TAS-115 
orally once daily and/or bevacizumab 
intraperitoneally once a week. Tumor 
volume was measured using calipers. 
Mean ± SE tumor volumes on day 
39 are shown for groups containing 
five mice each. The data shown are 
representative of two independent 
experiments with similar results. HGF, 
hepatocyte growth factor.
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TAS-115 may impair the function of endothelial progenitor 
cells expressing VEGFR-2. Further studies with longer follow-
up and histochemical analysis will be required to determine 
the exact mechanisms. On the other hand, VEGFR inhibitory 
activity may be the disadvantage of TAS-115 for specific cases 
in which EGFR-TKI resistance caused by only MET amplifi-
cation. Previous study reported that anti-VEGF therapy elicits 
malignant progression of tumors to increased local invasion 
and distant metastasis.37 Therefore, biomarkers for detecting 
the activities of MET and VEGFRs may be necessary for the 
optimal use of dual inhibitors for MET and VEGFR.
Inhibition of multiple signaling pathways may cause 
severe adverse events, especially with continuous admiration 
of the inhibitors. In our study, 50 mg/kg erlotinib administered 
daily plus 100 μg/body bevacizumab administered weekly did 
not show obvious adverse events in nude mice. However, some 
nude mice treated with daily 50 mg/kg crizotinib plus daily 
50 mg/kg erlotinib exhibited severe weight loss and died. Thus, 
we had to reduce the dose of crizotinib to 25 mg/kg daily when 
administered along with 50 mg/kg erlotinib. On the other hand, 
daily administration of 75 mg/kg TAS-115, as expected, inhib-
ited its two targets, Met phosphorylation and angiogenesis, 
in vivo, and did not show obvious adverse events, including 
weight loss, even in combination with daily administration of 
50 mg/kg erlotinib, suggesting the feasibility of this combined 
treatment. However, the safety and efficacy of triple inhibition 
with the triplet of clinically available drugs or with erlotinib 
plus TAS-115 need to be carefully evaluated in clinical trials.
In conclusion, we demonstrated that triple inhibition 
of EGFR, Met, and angiogenesis could be achieved by a 
combination of clinically available drugs (erlotinib, crizo-
tinib, and bevacizumab) or erlotinib and TAS-115 and that 
the triple inhibition efficiently controlled growth of HGF-
triggered, EGFR-TKI–resistant tumors containing EGFR 
mutations. Clinical trials are warranted to evaluate the 
efficacy and safety of the triple inhibition in EGFR-mutant 
lung cancer patients who acquired EGFR-TKI resistance 
due to HGF.
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